Selpercatinib monotherapy (LIBRETTO-001) — RET fusion+ NSCLC
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-SELPERCATINIB |
|---|
| ID | REG-SELPERCATINIB-NSCLC |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-LIBRETTO001-DRILON-2020 SRC-NCCN-NSCLC-2025 |
Notes
LIBRETTO-001 NSCLC: pretreated ORR 64% (mPFS 16.5 mo); TKI-naive ORR 85%; intracranial ORR 91%. FDA approval 2020 for RET-fusion+ NSCLC any line. LIBRETTO-431 phase-3 vs platinum±pembrolizumab: PFS HR 0.46 confirmed 1L superiority. Pralsetinib (ARROW) alternative.
Used By
Indication
IND-NSCLC-2L-RET-FUSION-SELPERCATINIB- IND-NSCLC-2L-RET-FUSION-SELPERCATINIBIND-NSCLC-RET-FUSION-1L-SELPERCATINIB- IND-NSCLC-RET-FUSION-1L-SELPERCATINIB